Profound Thrombocytopenia in Previously Treated Patients with Recurrent Ovarian Carcinoma Receiving Topotecan

By Cass I.   Kuo D.Y.   Fields A.L.   Runowicz C.D.   Goldberg G.L.  

Gynecologic Oncology, Vol. 69, Iss. 2, 1998-05 ,pp. : 175-176

Elsevier

Access to resources Recommend Favorite

A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma

By Rose P.G.   Gordon N.H.   Fusco N.   Fluellen L.   Rodriguez M.   Ingalls S.T.   Hoppel C.L.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 228-234

Elsevier

Access to resources Recommend Favorite

Efficacy and Hematologic Toxicity of Salvage Chemotherapy Following Stem Cell-Supported High-Dose Chemotherapy in Women with Recurrent Ovarian Cancer

By Cook S.   Penson R.   Duska L.   Nikrui N.   Goodman A.   Fuller A.   Seiden M.  

Gynecologic Oncology, Vol. 77, Iss. 1, 2000-04 ,pp. : 48-54

Elsevier

Access to resources Recommend Favorite

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Markman M.   Blessing J.A.   Alvarez R.D.   Hanjani P.   Waggoner S.   Hall K.  

Gynecologic Oncology, Vol. 77, Iss. 1, 2000-04 ,pp. : 112-115

Elsevier

Access to resources Recommend Favorite

Complete Response to Topotecan of Recurrent Fallopian Tube Carcinoma

By Dunton C.J.   Neufeld J.  

Gynecologic Oncology, Vol. 76, Iss. 1, 2000-01 ,pp. : 128-129

Elsevier

Access to resources Recommend Favorite